Literature DB >> 17196367

Protein kinase D 3 is localized in vesicular structures and interacts with vesicle-associated membrane protein 2.

Ganwei Lu1, Jun Chen, Luis A Espinoza, Susan Garfield, Saito Toshiyuki, Hayashi Akiko, Anna Huppler, Q Jane Wang.   

Abstract

Protein kinase D localizes in the Golgi and regulates protein transport from the Golgi to the plasma membrane. In the present study, we found that PKD3, a novel member of the PKD family, and its fluorescent protein fusions localized in the Golgi and in the vesicular structures that are in part marked by endosome markers. Fluorescent recovery after photobleaching (FRAP) showed that the PKD3-associated vesicular structures were constantly forming and dissolving, reflecting active subcellular structures. FRAP on plasma membrane-located PKD3 indicated a slower recovery of PKD3 fluorescent signal compared to those of PKC isoforms, implying a different targeting mechanism at the plasma membrane. VAMP2, the vesicle-localized v-SNARE, was later identified as a novel binding partner of PKD3 through yeast two-hybrid screening. PKD3 directly interacted with VAMP2 in vitro and in vivo, and colocalized in part with VAMP2 vesicles in cells. PKD3 did not phosphorylate VAMP-GFP and the purified GST-VAMP2 protein in in vitro phosphorylation assays. Rather, PKD3 was found to promote the recruitment of VAMP2 vesicles to the plasma membrane in response to PMA, while the kinase dead PKD3 abolished this effect. Thus, the kinase activity of PKD3 was required for PMA-induced plasma membrane trafficking of VAMP2. In summary, our findings suggest that PKD3 localizes to vesicular structures that are part of the endocytic compartment. The vesicular distribution may be attributed in part to the direct interaction between PKD3 and vesicle-associated membrane protein VAMP2, through which PKD3 may regulate VAMP2 vesicle trafficking by facilitating its recruitment to the target membrane.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17196367     DOI: 10.1016/j.cellsig.2006.10.012

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  17 in total

1.  Role of protein kinase d in Golgi exit and lysosomal targeting of the transmembrane protein, Mcoln1.

Authors:  David L Marks; Eileen L Holicky; Christine L Wheatley; Ayala Frumkin; Gideon Bach; Richard E Pagano
Journal:  Traffic       Date:  2012-02-16       Impact factor: 6.215

2.  Inducible silencing of protein kinase D3 inhibits secretion of tumor-promoting factors in prostate cancer.

Authors:  Courtney R LaValle; Liyong Zhang; Shuping Xu; Julie L Eiseman; Q Jane Wang
Journal:  Mol Cancer Ther       Date:  2012-04-24       Impact factor: 6.261

3.  Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation.

Authors:  Bettina Huck; Stephan Duss; Angelika Hausser; Monilola A Olayioye
Journal:  J Biol Chem       Date:  2013-12-11       Impact factor: 5.157

4.  GIT1 phosphorylation on serine 46 by PKD3 regulates paxillin trafficking and cellular protrusive activity.

Authors:  Bettina Huck; Ralf Kemkemer; Mirita Franz-Wachtel; Boris Macek; Angelika Hausser; Monilola A Olayioye
Journal:  J Biol Chem       Date:  2012-08-13       Impact factor: 5.157

5.  Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone.

Authors:  Elizabeth R Sharlow; Karthik V Giridhar; Courtney R LaValle; Jun Chen; Stephanie Leimgruber; Rebecca Barrett; Karla Bravo-Altamirano; Peter Wipf; John S Lazo; Q Jane Wang
Journal:  J Biol Chem       Date:  2008-09-30       Impact factor: 5.157

6.  Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility.

Authors:  Courtney R Lavalle; Karla Bravo-Altamirano; Karthik V Giridhar; Jun Chen; Elizabeth Sharlow; John S Lazo; Peter Wipf; Q Jane Wang
Journal:  BMC Chem Biol       Date:  2010-05-05

7.  In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts.

Authors:  Jianxia Guo; Dana M Clausen; Jan H Beumer; Robert A Parise; Merrill J Egorin; Karla Bravo-Altamirano; Peter Wipf; Elizabeth R Sharlow; Qiming Jane Wang; Julie L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  2012-10-30       Impact factor: 3.333

8.  Both the establishment and maintenance of neuronal polarity require the activity of protein kinase D in the Golgi apparatus.

Authors:  Dong-Min Yin; Yan-Hua Huang; Yan-Bing Zhu; Yun Wang
Journal:  J Neurosci       Date:  2008-08-27       Impact factor: 6.167

9.  PKD3 is the predominant protein kinase D isoform in mouse exocrine pancreas and promotes hormone-induced amylase secretion.

Authors:  L Andy Chen; Jing Li; Scott R Silva; Lindsey N Jackson; Yuning Zhou; Hiroaki Watanabe; Kirk L Ives; Mark R Hellmich; B Mark Evers
Journal:  J Biol Chem       Date:  2008-11-21       Impact factor: 5.157

10.  Cleavage of protein kinase D after acute hypoinsulinemia prevents excessive lipoprotein lipase-mediated cardiac triglyceride accumulation.

Authors:  Min Suk Kim; Fang Wang; Prasanth Puthanveetil; Girish Kewalramani; Sheila Innis; Lucy Marzban; Susan F Steinberg; Travis D Webber; Timothy J Kieffer; Ashraf Abrahani; Brian Rodrigues
Journal:  Diabetes       Date:  2009-11       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.